112 related articles for article (PubMed ID: 9719630)
1. Epstein-Barr virus-infected marmoset cells transfected with c-myc do not form lymphomas in mice with severe combined immunodeficiency.
Salimi B; O'Gorman MR; Variakojis D; Bendet M; Newman M; Poupko E; Katz BZ
Mol Genet Metab; 1998 Jul; 64(3):205-12. PubMed ID: 9719630
[TBL] [Abstract][Full Text] [Related]
2. Epstein-Barr virus-infected marmoset cells do not form lymphomas in mice with severe combined immunodeficiency.
Katz BZ; Salimi B; Saini U; McNamara JG; Eisen R
Pediatr Res; 1994 Oct; 36(4):456-60. PubMed ID: 7816520
[TBL] [Abstract][Full Text] [Related]
3. [Molecular pathological characteristics of human B-cell lymphomas induced by Epstein-Barr virus].
Gan RL; Yin ZH; Liu TF; Dong BH; Zhou JG; Yao KT
Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Oct; 35(10):925-9. PubMed ID: 14515211
[TBL] [Abstract][Full Text] [Related]
4. The in vivo binding site for oncoprotein c-Myc in the promoter for Epstein-Barr virus (EBV) encoding RNA (EBER) 1 suggests a specific role for EBV in lymphomagenesis.
Niller HH; Salamon D; Ilg K; Koroknai A; Banati F; Bauml G; Rucker O; Schwarzmann F; Wolf H; Minarovits J
Med Sci Monit; 2003 Jan; 9(1):HY1-9. PubMed ID: 12552250
[TBL] [Abstract][Full Text] [Related]
5. MYC overexpression imposes a nonimmunogenic phenotype on Epstein-Barr virus-infected B cells.
Staege MS; Lee SP; Frisan T; Mautner J; Scholz S; Pajic A; Rickinson AB; Masucci MG; Polack A; Bornkamm GW
Proc Natl Acad Sci U S A; 2002 Apr; 99(7):4550-5. PubMed ID: 11917131
[TBL] [Abstract][Full Text] [Related]
6. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder.
Roychowdhury S; Baiocchi RA; Vourganti S; Bhatt D; Blaser BW; Freud AG; Chou J; Chen CS; Xiao JJ; Parthun M; Chan KK; Eisenbeis CF; Ferketich AK; Grever MR; Chen CS; Caligiuri MA
J Natl Cancer Inst; 2004 Oct; 96(19):1447-57. PubMed ID: 15467034
[TBL] [Abstract][Full Text] [Related]
7. Model of angiogenesis in mice with severe combined immunodeficiency (SCID) and xenoengrafted with Epstein-Barr virus-transformed B cells.
Woodford NL; Call DR; Remick DG; Rochford R
Comp Med; 2004 Apr; 54(2):209-15. PubMed ID: 15134368
[TBL] [Abstract][Full Text] [Related]
8. The nitroreductase/CB1954 combination in Epstein-Barr virus-positive B-cell lines: induction of bystander killing in vitro and in vivo.
Westphal EM; Ge J; Catchpole JR; Ford M; Kenney SC
Cancer Gene Ther; 2000 Jan; 7(1):97-106. PubMed ID: 10678362
[TBL] [Abstract][Full Text] [Related]
9. Lack of pseudotype formation between human immunodeficiency virus type 1 and Epstein-Barr virus in productively coinfected B lymphoblastoid cell lines.
Van Kuyk R; Mosier DE
Virology; 1995 Jun; 209(2):643-8. PubMed ID: 7778296
[TBL] [Abstract][Full Text] [Related]
10. Expression of the simian Epstein-Barr virus-encoded latent membrane protein-1 in malignant lymphomas of SIV-infected rhesus macaques.
Blaschke S; Hannig H; Buske C; Kaup FJ; Hunsmann G; Bodemer W
J Med Virol; 2001 Sep; 65(1):114-20. PubMed ID: 11505452
[TBL] [Abstract][Full Text] [Related]
11. The role of natural-killer-cells in the pathogenesis of epstein-barr virus-associated burkitt-lymphoma in a scid mouse model.
Katz B; Salimi B; Saini U; McNamara J; Eisen R
Int J Oncol; 1994 Jan; 4(1):225-9. PubMed ID: 21566917
[TBL] [Abstract][Full Text] [Related]
12. Bcl-2 antisense oligodeoxynucleotide therapy of Epstein-Barr virus-associated lymphoproliferative disease in severe combined immunodeficient mice.
Guinness ME; Kenney JL; Reiss M; Lacy J
Cancer Res; 2000 Oct; 60(19):5354-8. PubMed ID: 11034070
[TBL] [Abstract][Full Text] [Related]
13. Epstein-Barr virus-induced human B-cell lymphomas in SCID mice reconstituted with human peripheral blood leukocytes.
Mosier DE; Picchio GR; Baird SM; Kobayashi R; Kipps TJ
Cancer Res; 1992 Oct; 52(19 Suppl):5552s-5553s. PubMed ID: 1327510
[TBL] [Abstract][Full Text] [Related]
14. Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: a potential therapeutic approach to EBV-associated lymphoproliferative diseases.
Srimatkandada P; Loomis R; Carbone R; Srimatkandada S; Lacy J
Eur J Haematol; 2008 May; 80(5):407-18. PubMed ID: 18221384
[TBL] [Abstract][Full Text] [Related]
15. Human-->mouse radiation chimera do not develop Epstein-Barr virus lymphoma.
Marcus H; Burakova T; Shezen E; David M; Canaan A; Lubin I; Reisner Y
Immunol Lett; 1996 Mar; 49(3):155-61. PubMed ID: 8739310
[TBL] [Abstract][Full Text] [Related]
16. c-MYC impairs immunogenicity of human B cells.
Schlee M; Schuhmacher M; Hölzel M; Laux G; Bornkamm GW
Adv Cancer Res; 2007; 97():167-88. PubMed ID: 17419945
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of HHV-8/KSHV infected primary effusion lymphomas in NOD/SCID mice by azidothymidine and interferon-alpha.
Wu W; Rochford R; Toomey L; Harrington W; Feuer G
Leuk Res; 2005 May; 29(5):545-55. PubMed ID: 15755507
[TBL] [Abstract][Full Text] [Related]
18. EBV-induced human B cell lymphomas in hu-PBL-SCID mice.
Mosier DE; Picchio GR; Kirven MB; Garnier JL; Torbett BE; Baird SM; Kobayashi R; Kipps TJ
AIDS Res Hum Retroviruses; 1992 May; 8(5):735-40. PubMed ID: 1325170
[TBL] [Abstract][Full Text] [Related]
19. Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab.
Loomis R; Carbone R; Reiss M; Lacy J
Clin Cancer Res; 2003 May; 9(5):1931-9. PubMed ID: 12738752
[TBL] [Abstract][Full Text] [Related]
20. Induction of lytic Epstein-Barr virus (EBV) infection in EBV-associated malignancies using adenovirus vectors in vitro and in vivo.
Westphal EM; Mauser A; Swenson J; Davis MG; Talarico CL; Kenney SC
Cancer Res; 1999 Apr; 59(7):1485-91. PubMed ID: 10197618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
